Literature DB >> 31934033

Expression of FXR and HRG and their clinicopathological significance in benign and malignant pancreatic lesions.

Xue-Liang Chen1, Ke-Xin Xie2, Zhu-Lin Yang3, Lian-Wen Yuan1.   

Abstract

AIMS: The following study examines the FXR and HRG expression in benign and malignant lesions of the pancreas and evaluates the association between FXR and HRG expression with clinicopathological features and prognosis of pancreatic cancer.
MATERIALS AND METHODS: Immunohistochemistry of FXR and HRG was performed with EnVision™ in 106 pancreatic ductal adenocarcinoma (PDAC) specimens, 35 paracancer samples (2 cm away from the tumor, when possible or available), 55 benign lesions and 13 normal tissue samples.
RESULTS: The percentage of cases with positive FXR and negative HRG expression was significantly higher in PDAC compared to pericancerous tissues, benign lesions and normal tissues (P<0.05 or P<0.01). In pancreatic tissues with benign lesions, tissues with positive FXR and/or negative HRG protein expression exhibited dysplasia or intraepithelial neoplasia. The percentage of cases with positive FXR and negative HRG expressions was significantly higher in PDAC with lymph node metastasis, invasion, and TNM stage III+IV disease (P<0.05 or P<0.01). The expression of FXR was negatively correlated with HRG (P<0.05). In addition, the univariate Kaplan-Meier analysis showed that positive FXR and negative HRG expression, poor differentiation, large tumor size, high TNM stage, lymph node metastasis, and invasion were closely associated with decreased overall survival in PDAC patients (P<0.05 or P<0.01). Moreover, multivariate Cox regression analysis identified that positive FXR and negative HRG expression were independent factors for poor prognosis in PDAC. The AUC for FXR was (AUC=0.709, 95% CI: 0.632-0.787), and for HRG was (AUC=0.719, 95% CI: 0.643-0.796) in PDAC compared to benign lesions.
CONCLUSIONS: Positive FXR and negative HRG expression are closely associated with the carcinogenesis, clinical, pathological and biological behaviors, and poor prognosis in PDAC. IJCEP
Copyright © 2019.

Entities:  

Keywords:  FXR; HRG; Pancreatic ductal adenocarcinoma; dysplasia; immunohistochemistry; pancreatic intraepithelial neoplasia

Year:  2019        PMID: 31934033

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  5 in total

Review 1.  Farnesoid X receptor: a potential therapeutic target in multiple organs.

Authors:  Chao Zhang; Zixuan Wang; Qingqing Feng; Wei-Dong Chen; Yan-Dong Wang
Journal:  Histol Histopathol       Date:  2021-01-04       Impact factor: 2.303

Review 2.  Oncobiosis and Microbial Metabolite Signaling in Pancreatic Adenocarcinoma.

Authors:  Borbála Kiss; Edit Mikó; Éva Sebő; Judit Toth; Gyula Ujlaki; Judit Szabó; Karen Uray; Péter Bai; Péter Árkosy
Journal:  Cancers (Basel)       Date:  2020-04-25       Impact factor: 6.639

Review 3.  Targeting Farnesoid X receptor (FXR) for developing novel therapeutics against cancer.

Authors:  Sosmitha Girisa; Sahu Henamayee; Dey Parama; Varsha Rana; Uma Dutta; Ajaikumar B Kunnumakkara
Journal:  Mol Biomed       Date:  2021-07-10

4.  Identification of potential core genes in colorectal carcinoma and key genes in colorectal cancer liver metastasis using bioinformatics analysis.

Authors:  Lipeng Niu; Ce Gao; Yang Li
Journal:  Sci Rep       Date:  2021-12-14       Impact factor: 4.379

5.  Decreased expression of farnesoid X receptor may indicate poor prognosis in patients with colorectal cancer.

Authors:  Danying Zhang; Shuqiang Weng; Can Cui; Ling Dong; Xizhong Shen
Journal:  Transl Cancer Res       Date:  2020-07       Impact factor: 1.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.